Former Medtronic Neuromodulation VP Jumps to Johnson & Johnson's DePuy Synthes as Global Trauma President

Recently, DePuy Synthes, the orthopedics business unit of Johnson & Johnson, announced on its official self-media platforms thatPaolo Di Vincenzo Officially Appointed as Global President of Trauma Business, based in West Chester, Pennsylvania, USA. Public information indicates that this is Paolo Di Vincenzo’s first time joining the Johnson & Johnson system in his career.

Before joining Johnson & Johnson, Paolo Di Vincenzo’s previous well-known role wasMedtronicPresident, Neuromodulation BusinessSince October 2023, he has been leading this high-growth, high-barrier neuroscience segment in Minneapolis for over two and a half years.

Earlier, he was atSmith & NephewHaving spent nearly a decadeHis most recent position was Senior Vice President and General Manager of the Advanced Wound Care business in the United States. During this period, he was also stationed in London and Dubai, where he was responsible for global marketing and the Asia-Pacific and emerging markets segments of the business, respectively, thereby completing the management cycle from regional to global markets.

Moving further along the timeline, his career path also encompassedBDandRoche, and has spanned multiple functions within the Roche system, including finance, intellectual property strategy, and brand management. Notably, his international rotation trajectory has involved multiple markets such as the United Kingdom, Singapore, Germany, Switzerland, Portugal, and the United States.

If these clues are pieced together, it can be seen thatThis is a manager whose career spans three major business segments—Neuromodulation, Wound Care, and Orthopedic Trauma—and who possesses practical experience ranging from emerging markets to mature markets in Europe and the United States.His functional scope simultaneously covers marketing, general management, and financial projects.

DePuy Synthes has long held a market leadership position in the field of orthopedic trauma,In selecting a global president for a mature and dominant business unit, Johnson & Johnson’s choice of criteria itself sends a signal worthy of industry reflection.

On the one hand, Paolo Di Vincenzo’s appointment breaks with the traditional practice of either promoting from within the orthopedics division or hiring directly from competitors. His core expertise does not stem from the conventional orthopedic implant sector, but rather spans two related yet logically distinct tracks—Neuromodulation centered on implantable devices, algorithms, and services, as well as wound care centered on advanced dressings and negative pressure therapy.

On the other hand, reviewing DePuy Synthes' developments over the past two years reveals that its initiatives have not been limited to implants alone. From advancing the digital surgical ecosystem to exploring tighter integration of preoperative planning, intraoperative navigation, and implantable products into a more cohesive closed-loop system,The company’s definition of “solutions” is expanding outward.At this juncture, the appointment of a manager who possesses deep expertise in the value cycle of implantable devices, has managed large-scale consumables businesses, and has firsthand experience with the complexities of emerging markets suggests that the underlying intent may extend beyond routine personnel replacement.